Drug Formulation Development Case Studies | Velesco Pharma
Expert Solutions to Challenging Drug Formulation Projects
Challenge: drug formulation development using challenging vehicles
Velesco was contracted to create a common pharmaceutical formulation for four drug compounds to be dosed at multiple strengths using a clear aqueous vehicle.
Read the drug formulation development case study
Challenge: develop formulations for low solubility compounds with many delivery routes
Development of a drug formulation for a poorly soluble compound suitable for oral, intraperitoneal and intravenous use can be quite a challenge, but with our expertise, Velesco had the answer!
Read the drug formulation development case study
Challenge: high concentration pharmaceutical formulation development for compounds with low solubility using microemulsions
Velesco was asked to formulate a clear solution/microemulsion for a low solubility compound at a high concentration for an oral toxicity study, which was completed successfully.
Read the drug formulation development case study
Challenge: injectable formulations for poorly soluble drugs
Velesco developed an injectable formulation for a low solubility compound at a high dose using nucleation inhibitors.
Read the drug formulation development case study
Challenge: formulate drug product using active pharmaceutical ingredient (API) synthesized using different processes, addressing solubility issues.
Velesco was asked to formulate several different lots of material all displaying different characteristics.
Read the drug formulation development case study
News and Events
Newly Acquired DEA Analytical Laboratory License. We are licensed to use schedules 2, 2N, 3, 3N, 4, and 5.
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.
New Velesco Pharma clinical manufacturing facility begins operations. Read the press release here.
Lisa Crandall, MS, and Peter Angus, PhD, spoke with Pharmaceutical Technology about the best practices in stability testing. Read the interview here.
Velesco has expanded our analytical facilities in a new Wixom, Michigan location with the help of the Bank of Ann Arbor Technology Industry Group. Read the press release here.
CEO Dave Barnes has been published in a new Pharmoutsourcing article on Clinical Trial Materials and Manufacturing!
1 new job postings! Careers
Velesco's work published
Formulation Development & Manufacturing:
Using a Single Provider Reduces Costs & Risk
Read it here.
Follow Velesco:
734-274-9877